Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Halozyme Therapeutics

- PMLiVE

Novo Nordisk recalls insulin

Batches of prefilled NovoMix 30 pens found to have incorrect amount of diabetes treatment

- PMLiVE

Ariad tanks as Iclusig trial is halted on safety grounds

Shares fall after leukaemia patients develop blood clots

- PMLiVE

Communications rethink for Health Canada

Government review of regulator’s outreach efforts follows recall of birth-control drug

- PMLiVE

Ariad halts patient enrolment for cancer drug studies

Concerns raised after patients taking Iclusig experience blood clots and cardiovascular events

- PMLiVE

Translational pharmacology and drug dosing

The key to ensuring safe and effective dosing

- PMLiVE

EU launches black triangle drug monitoring scheme

New pharmacovigilance symbol will be used by all drugs needing additional monitoring

- PMLiVE

Celgene wins US pancreatic cancer indication for Abraxane

Adds to breast cancer and lung cancer indications

- PMLiVE

FDA investigates safety of Novartis’ MS drug

Agency to determine association between Gilenya and rare brain infection

Biogen Idec building

Patient death probably not linked to Biogen Idec’s Tecfidera

Stock recovers after unfounded claims

- PMLiVE

Celgene halts Revlimid trial after patient deaths

High mortality rate in trial involving elderly patients with rare leukaemia

- PMLiVE

EMA in firing line as transparency debate widens

Swedish regulator claims EU agency withheld information on drug withdrawn from sale in 2008

Roche - Basel

Late-stage blow to Roche’s diabetes ambitions

Halts development of aleglitazar on safety and efficacy concerns

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links